# JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation

> **NCT05194995** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Allist Pharmaceuticals, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Advanced Colorectal Cancer
- Small Intestinal Cancer
- Appendiceal Cancer

## Interventions

- **DRUG:** JAB-21822
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT05194995
- **Lead sponsor:** Allist Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-02-17
- **Primary completion:** 2025-04-30
- **Final completion:** 2026-12
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2026-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05194995

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05194995, "JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05194995. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*